The SARS-CoV-2 infection has caused a serious public health threat globally with over 6 million deaths reported. Despite large-scale vaccination around the world, the infection rate remains high due to rapid mutations of the coronavirus, which warrants the development of novel therapeutic agents for the treatment of COVID-19. Treatment guidelines in both China and the U.S. have been updated on their recommendations regarding the recent authorizations of Paxlovid and bebtelovimab. This paper focuses on the four newly authorized agents, Paxlovid, molnupiravir, bebtelovimab, and amubarvimab/romlusevimab, for a review of their mechanisms, development progress, and clinical evidence. The characteristics and comparative use of the above agents are discussed to provide perspectives for current practice and future development.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |